The effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: A preliminary study

Neuropsychiatric Disease and Treatment

Volumn 10, Issue , 2014, Pages 1571-1576

  Hashimoto, Kojiro ^a   Sugawara, Norio ^a   Ishioka, Masamichi ^a   Nakamura, Kazuhiko ^a   Yasui Furukori, Norio ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

Adjunctive treatment; Hyperprolactinemia; Schizophrenia; Terguride

Indexed keywords

BIPERIDEN; DIAZEPAM; FLUNITRAZEPAM; PALIPERIDONE; PROLACTIN; RISPERIDONE; SENNOSIDE; TERGURIDE;

ADD ON THERAPY; ADULT; ARTICLE; BEDTIME DOSAGE; BODY HEIGHT; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DISEASE DURATION; DRUG TOLERABILITY; ENZYME IMMUNOASSAY; FEMALE; HALLUCINATION; HUMAN; HYPERPROLACTINEMIA; INSOMNIA; MALE; MORNING DOSAGE; PROLACTIN BLOOD LEVEL; PROTEIN ANALYSIS; PROTEIN FUNCTION; RESTLESSNESS; SCHIZOPHRENIA; SEX DIFFERENCE; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84907317029     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S68298     Document Type: Article

References (32)

1. Byerly M, Suppes T, Tran QV, Baker RA. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol. 2007; 27(6): 639-661.
2. Bostwick JR, Guthrie SK, Ellingrod VL. Antipsychotic-induced hyperprolactinemia. Pharmacotherapy. 2009; 29(1): 64-73.
3. Meaney AM, Smith S, Howes OD, O'Brien M, Murray RM, O'Keane V. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry. 2004; 184: 503-508.
4. Costa AM, Lima MS, Mari Jde J. A systematic review on clinical management of antipsychotic-induced sexual dysfunction in schizophrenia. Sao Paulo Med J. 2006; 124(5): 291-297.
5. Wachtel H, Dorow R. Dual action on central dopamine function of transdihydrolisuride, a 9, 10-dihydrogenated analogue of the ergot dopamine agonist lisuride. Life Sci. 1983; 32(4): 421-432.
6. Kehr W. Transdihydrolisuride, a partial dopamine receptor antagonist: effects on monoamine metabolism. Eur J Pharmacol. 1984; 97(1-2): 111-119.
7. Stephens DN, Löschmann PA, Lanzinger C, Wachtel H, Montgomery AM, Herberg LJ. Unusual interactions between the neuroleptic haloperidol, and the dopamine D2 partial agonist, terguride. Behav Pharmacol. 1990; 1(6): 521-529.
8. Yamaguchi M, Kimura-Iwasaki K, Akai T, Nakada Y, Nakagawa H. Terguride, a dopamine D(2) partial agonist, as a discriminative stimulus in rats. Behav Pharmacol. 1991; 2(3): 233-240.
9. Wachtel H, Dorow R, Sauer G. Novel 8 alpha-ergolines with inhibitory and stimulatory effects on prolactin secretion in rats. Life Sci. 1984; 35(18): 1859-1867.
10. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987; 334: 1-100.
11. Venturini PL, Horowski R, Valenzano M, et al. Effect of terguride on prolactin levels in normal, puerperal and hyperprolactinaemic women. Eur J Clin Pharmacol. 1986; 30(2): 195-197.
12. Ciccarelli E, Touzel R, Besser M, Grossman A. Terguride-a new dopamine agonist drug: a comparison of its neuroendocrine and side effect profile with bromocriptine. Fertil Steril. 1988; 49(4): 589-594.
13. Větr M, Talas M, Pohanka J, Gazárek F, Fingerová H. Terguride in the treatment of hyperprolactinemia. Acta Univ Palacki Olomuc Fac Med. 1990; 125: 155-160.
14. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002; 63(9): 763-771.
15. Casey DE, Carson WH, Saha AR, et al. Aripiprazole Study Group. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl). 2003; 166(4): 391-399.
16. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebocontrolled trials. Schizophr Res. 2003; 61(2-3): 123-136.
17. Lin SK, Chen CK. Reversal of antipsychotic-induced hyperprolactinemia, weight gain, and dyslipidemia by aripiprazole: a case report. J Clin Psychiatry. 2006; 67(8): 1307.
18. Wahl R, Ostroff R. Reversal of symptomatic hyperprolactinemia by aripiprazole. Am J Psychiatry. 2005; 162(8): 1542-1543.
19. Lee BH, Kim YK, Park SH. Using aripiprazole to resolve antipsychoticinduced symptomatic hyperprolactinemia: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2006; 30(4): 714-717.
20. Wolf J, Fiedler U. Hyperprolactinemia and amenorrhea associated with olanzapine normalized after addition of aripiprazole. J Clin Pharm Ther. 2007; 32(2): 197-198.
21. Shim JC, Shin JG, Kelly DL, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry. 2007; 164(9): 1404-1410.
22. Chen CH, Huang MC, Lu ML. Aripiprazole resolves symptomatic hyperprolactinemia in a male schizophrenic patient. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32(3): 893-894.
23. Lu ML, Shen WW, Chen CH. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32(8): 1978-1981.
24. Mir A, Shivakumar K, Williamson RJ, McAllister V, O'Keane V, Aitchison KJ. Change in sexual dysfunction with aripiprazole: a switching or add-on study. J Psychopharmacol. 2008; 22(3): 244-253.
25. Sheldrick AJ, Gründer G. Aripiprazole reduces serum prolactin in a woman with prolactinoma and acute psychosis. Pharmacopsychiatry. 2008; 41(4): 160.
26. Byerly MJ, Marcus RN, Tran QV, Eudicone JM, Whitehead R, Baker RA. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. Schizophr Res. 2009; 107(2-3): 218-222.
27. Yasui-Furukori N, Kaneda A, Sugawara N, Tomita T, Kaneko S. Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients. J Psychopharmacol. 2012; 26(6): 806-812.
28. Yasui-Furukori N, Furukori H, Sugawara N, Fujii A, Kaneko S. Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia. J Clin Psychopharmacol. 2010; 30(5): 596-599.
29. Hori H, Yoshimura R, Katsuki A, Sugita AI, Atake K, Nakamura J. Switching to antipsychotic monotherapy can improve attention and processing speed, and social activity in chronic schizophrenia patients. J Psychiatr Res. 2013; 47(12): 1843-1848.
30. Tadori Y, Miwa T, Tottori K, et al. Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. Eur J Pharmacol. 2005; 515(1-3): 10-19.
31. Tadori Y, Kitagawa H, Forbes RA, McQuade RD, Stark A, Kikuchi T. Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912. Eur J Pharmacol. 2007; 574(2-3): 103-111.
32. Urichuk L, Prior TI, Dursun S, Baker G. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008; 9(5): 410-418.